Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000560

Drug Information
NameDonepezil    
SynonymsDB00843; Eranz; KBio2_002144; AC-6969; KBioSS_002144; Donepezil (INN); I06-0343; ( inverted exclamation markA)-E 2020; 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine; Donepezil; D07869; Spectrum5_001662; KBio2_004712; Donaz (TN); donepezil; CHEMBL502; AC1L1FAE; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one; 120014-06-4; AB1004836; MolPort-003-847-014; Spectrum_001664; UNII-8SSC91326P; Donaz; MolPort-000-881-588; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; TL8000531; AKOS000277311; NCGC00167537-01; C24H29NO3; KBio2_007280; Oprea1_188452; LS-81819; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-; CHEBI:53289; CID3152; Donepezil [INN:BAN]    
Trade NameAricept    
CompanyPfizer Pharmaceuticals    
IndicationAlzheimer's diseaseApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassParasympathomimetics    
CAS NumberCAS 120014-06-4
FormularC24H29NO3    
PubChem Compound IDCID 3152.    
PubChem Substance IDSID 196718.    
SuperDrug ATC IDN06DA02;    
SuperDrug CAS ID120014064;    
TargetAcetylcholinesteraseInhibitor[2][3][4][5]
Ref 1Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. To Reference
Ref 2From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33. Epub 2009 Jun 5. To Reference
Ref 3Effects of chronic donepezil treatment and cholinergic deafferentation on parietal pyramidal neuron morphology. J Alzheimers Dis. 2009 May;17(1):177-91. To Reference
Ref 4Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85. To Reference
Ref 5Towards a high-affinity allosteric enhancer at muscarinic M1 receptors. J Mol Neurosci. 2002 Aug-Oct;19(1-2):123-7. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543